U S Stem Cell Stock Price, News & Analysis
Company Description
U S Stem Cell (OTC Link: USRM) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $64.2K.
USRM stock has gained 0.0% over the past year. Shares last traded at $0.0001.
On a trailing twelve-month basis, U S Stem Cell reported revenue of $82K with net income of -$2.9M. The company operates at a net profit margin of -3483.2%.
This page provides a comprehensive overview of USRM stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
U S Stem Cell (USRM) stock last traded at $0.0001. At a market capitalization of $64.2K, USRM is classified as a micro-cap stock with approximately 641.5M shares outstanding.
Latest News
U S Stem Cell has 6 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 3 with negative movement. View all USRM news →
SEC Filings
Financial Highlights
U S Stem Cell generated $82K in revenue over the trailing twelve months, retaining a 71.0% gross margin, operating income reached -$1.7M (-2096.9% operating margin), and net income was -$2.9M, reflecting a -3483.2% net profit margin. The company generated -$305K in operating cash flow. With a current ratio of 0.00, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
USRM Company Profile & Sector Positioning
U S Stem Cell (USRM) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing USRM often look at related companies in the same sector, including Reneuron Group (RNUGF), Syros Pharmaceut (SYRS), Aridis Pharmaceuticals Inc (ARDS), Adhera Therapeutics Inc (ATRX), and GB Sciences (GBLX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate USRM's relative position within its industry.